Yoko Bian is a science advisor in the firm’s Litigation department and a member of its Intellectual Property practice. She contributes to the firm’s work in patent litigation, patent opinions, and due diligence. Dr. Bian has worked on cases and matters including complex technologies including web-based software, 3D printing, OLED and LCD displays, telematics, and orthopaedic devices. Dr. Bian joined the firm in 2022.
Prior to joining Goodwin, Dr. Bian obtained her PhD in Chemistry - Nanotechnology and Materials Science from the Graduate Center, the City University of New York. Her doctoral research focuses on in silico design of proton conductive histidine-based biomimetic nanostructures. In part of Dr. Bian’s thesis, three major helical conformations with histidine side chains including 310-, α- and π-helices were investigated as potential candidates capable of conducting protons. The structures constructed were modeled using a hybrid computational approach with a semiempirical method (AM1) for peptide scaffolds and the more accurate density functional theory (B3LYP) for the proton wires. The proton wires formed upon hydrogen bonds between ε- and δ-nitrogens were computationally evaluated based on the difference in structural properties and the proton translocation energetics.
Dr. Bian is a member of the Asian American Bar Association of New York (AABANY), American Chemical Society (ACS), and American Society for Enology and Viticulture (ASEV).
Dr. Bian is also a member of the ChIPs Network and is a co-president of 500 Women Scientists NYC.
PhDNanotechnology and Materials Science2022
The Graduate Center, City University of New York
BSEconomics and Finance2016
Recognition & Awards
Dr. Bian is a member of Omicron Delta Epsilon (ODE), the International Honor Society in the field of Economics, and Omicron Delta Kappa (ODK) National Leadership Honor Society.
Dr. Bian is also a member of G20 Young Entrepreneurs’ Alliance.
Dr. Bian has presented her research at American Chemical Society National Conferences 2019, 2020 and 2021, and published scientific articles in peer-reviewed journals, including Int. J. Quantum Chem and J. Am. Chem. Soc. She is a contributor of Big Molecule Watch, Goodwin’s blog covering legal, business and regulatory developments involving biologics, biosimilars, and the Biologics Price Competition and Innovation Act (BPCIA).